Travere Therapeutics (TVTX) Q4 2025 earnings review
Breakout Quarter: GAAP Profitability Achieved as FILSPARI Accelerates
Travere delivered a watershed quarter, posting its first GAAP Net Income ($2.7M) in recent history, driven by a 108% YoY surge in FILSPARI sales to $103.3M. Commercial execution re-accelerated significantly with a record 908 Patient Start Forms (PSFs), dispelling fears of a plateau seen in Q3. With $322M in cash and the FSGS PDUFA date set for April 13, 2026, the company is pivoting from a cash-burning biotech to a profitable commercial operator, though launch costs for FSGS will likely pressure margins in the near term.
🐂 Bull Case
Fears of a Q3 slowdown were proven wrong. New Patient Start Forms (PSFs) jumped to a record 908 in Q4 from 731 in Q3. Sales grew 13.6% sequentially and 108% YoY, confirming strong demand elasticity.
The PDUFA date for FSGS is April 13, 2026. Approval would make FILSPARI the first and only FDA-approved treatment for this condition, opening a market potentially larger and faster-adopting than IgAN.
🐻 Bear Case
Profitability is fragile. SG&A expenses surged 46% YoY to $101.7M in Q4 to prep for the FSGS launch. Management signaled continued investment, which could dip the company back into losses temporarily in 2026.
Tiopronin (Thiola) sales declined 2.6% YoY to $23.3M. With generic competition looming (mentioned in prior calls), this segment is now a drag on top-line growth rather than a contributor.
⚖️ Verdict: 🟢🟢
Strong Bullish. Achieving GAAP profitability while growing the lead asset >100% is a rare feat in biotech. The re-acceleration in patient starts (908 vs 731 prev Q) validates the commercial strategy ahead of a major label expansion (FSGS).
Key Themes
Profitability Turnaround
Travere posted GAAP Net Income of $2.7M, a massive reversal from a $60.3M loss in 24Q4. This was driven by operating leverage: while Revenue grew 73% YoY, Operating Expenses only grew 20%, despite heavy launch investments.
FILSPARI Demand Surge
Accelerating. Patient Start Forms (PSFs)—a leading indicator for future revenue—hit an all-time high of 908. This follows a dip to 731 in Q3, confirming that the previous quarter's softness was seasonal or transient rather than structural.
SG&A Expense Inflation
Selling, General, and Administrative expenses ballooned to $101.7M in Q4, up from $86.5M in Q3 and $69.5M a year ago. Management attributes this to FSGS launch prep. While necessary, this burn rate requires sustained revenue hypergrowth to maintain positive earnings.
Pipeline Revival: HCU
The Pegtibatinase (Classical HCU) program is back on track. Enrollment activities for the pivotal Phase 3 HARMONY Study have resumed after manufacturing optimizations. This diversifies the long-term narrative beyond FILSPARI.
Legacy Portfolio Drag
Tiopronin products (Thiola) are stagnating, with sales of $23.3M in Q4 vs $23.9M a year ago (-2.6%). While FILSPARI is the growth engine, the legacy portfolio is no longer providing cash flow growth to subsidize the launch.
Other KPIs
Stable. Cash balance remains strong at $322.8M, effectively flat vs Q4 2024 ($312M marketable debt + cash was ~370M). The company expects a $25M milestone from Mirum in H1 2026, providing further runway without immediate dilution risk.
Stable. COGS remains negligible (2% of sales), maintaining pristine gross margins of ~98%. This high leverage allows revenue beats to flow almost directly to the bottom line.
Guidance
Upcoming Catalyst. The FDA PDUFA date is set. Approval would trigger a launch into a market with no approved therapies. The company states it is 'positioned for a successful commercial launch' immediately post-approval.
Partner Chugai Pharmaceutical expects to submit the New Drug Application (NDA) for sparsentan (FILSPARI) in Japan in 2026. This triggers potential milestone payments for Travere.
Expected in H1 2026. This non-dilutive capital injection strengthens the balance sheet during the high-spend launch window for FSGS.
Key Questions
SG&A Run Rate for FSGS
SG&A jumped to $101M this quarter. Should we model this as the new baseline, or will there be a further step-up in Q1/Q2 2026 to support the FSGS launch?
Gross-to-Net Dynamics
With the potential expansion into FSGS and Medicare Part D redesigns, how should we model gross-to-net adjustments for FY26 compared to the ~20% range seen in 2025?
Peak Sales Implications of 908 PSFs
With the record 908 PSFs, are you seeing a shift in the prescriber mix toward community nephrologists, and does this change your view on the peak penetration rate for IgAN specifically?